Fig. 6From: Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptorInhibition of tumor growth by erlotinib (ERL) in vivo. Mice were implanted with Ishikawa (a) or HEC-1A (b) and treated with ERL or TRA for 28 days. Tumor volume was measured twice a week. Data represent the means ± SEMs of three independent tumor volumes. *, decreased as compared to vehicle control, P < 0.05. c On day 28 after starting treatment, mice were euthanized and tumor was excised. The tissues were fixed in formalin and embedded in paraffin. Sections were taken from the paraffin-embedded tissue and HE stained. Top and upper middle panels, Ishikawa tumor; lower middle and bottom panels, HEC-1A tumor. Magnification × 200.Bars =1000 μmBack to article page